Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Schering-Plough and Novartis have extended their collaboration on combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The firms will combine mometasone, the corticosteroid active ingredient in Schering-Plough's Asmanex, and indacaterol, a β2-agonist being developed by Novartis, into a once-daily inhalation therapy. The companies will share development costs and copromote a combination therapy worldwide. The two currently have another combination therapy for asthma and COPD, composed of Asmanex and Novartis' Foradil, in Phase III clinical trials.
This article has been sent to the following recipient: